Crinetics stock price target raised to $75 from $58 at Stifel on Paltusotine approval

Carnival's stock has received a Buy rating from Stifel, reflecting strong booking trends for 2026. This positive outlook is significant as it indicates confidence in the company's recovery and growth potential in the cruise industry, which has faced challenges in recent years. Investors may find this news encouraging as it suggests a rebound in consumer interest and travel plans.

Piper Sandler has reaffirmed its Overweight rating on Crinetics Pharmaceuticals following the recent FDA approval of the company's new treatment. This endorsement is significant as it reflects confidence in Crinetics' growth potential and the positive impact of the FDA's decision on its stock performance. Investors are likely to view this as a strong signal for future success, making it an important development in the biotech sector.

Lamb Weston has received a stock rating of 'Hold' from Stifel, with a target price set at $61. This rating indicates that while the stock is not expected to decline significantly, it may not see substantial growth in the near term either. Investors should consider this cautious outlook as they evaluate their options in the food industry.

Stifel has decided to maintain its Hold rating on Waters Corporation's stock, even as the company plans to pursue acquisitions related to BD. This decision reflects a cautious approach to the potential impacts of these acquisitions on Waters' financial performance. Investors will be watching closely to see how these strategic moves unfold and what they mean for the company's future.

Birkenstock's stock has received a Buy rating from Stifel, highlighting the company's strong growth potential. This endorsement is significant as it reflects confidence in Birkenstock's market position and future performance, which could attract more investors and boost the brand's visibility in the competitive footwear industry.

Cytokinetics has received a Buy rating from Stifel, thanks to promising data on its drug aficamten. This positive assessment highlights the potential of aficamten in treating heart conditions, which could significantly impact patient care and the company's market position. Investors are optimistic about the future as this development may lead to increased stock value and greater interest in Cytokinetics' innovative therapies.

Stifel has reaffirmed its Buy rating on Outset Medical's stock, setting a price target of $17. This is significant as it reflects confidence in Outset Medical's growth potential and market position, which could attract more investors and positively impact the company's stock performance.

Verizon is reportedly in discussions to acquire wireless spectrum from EchoStar, according to Bloomberg News. This potential deal could enhance Verizon's network capabilities and expand its service offerings, which is significant in the competitive telecommunications market. If successful, this acquisition may lead to improved connectivity for customers and strengthen Verizon's position as a leader in the industry.

IDT Corporation has reported disappointing results for its Q4 2025 earnings, falling short of analysts' expectations. This miss raises concerns about the company's financial health and future performance, which could impact investor confidence and stock prices. Understanding these results is crucial for stakeholders as they navigate the implications for the company's strategy moving forward.

South Korea's used car exports are thriving, providing a buffer against the impact of US tariffs on the automotive sector. This surge in exports not only highlights the resilience of South Korean manufacturers but also reflects a growing global demand for affordable vehicles. As trade relations evolve, this trend could bolster the economy and create new opportunities for local businesses, making it a significant development in the automotive landscape.

YouTube has agreed to pay $24.5 million to settle a lawsuit regarding the suspension of former President Donald Trump's account. This settlement is significant as it highlights the ongoing debates around social media platforms' power to regulate content and the implications for free speech. The resolution of this case may set a precedent for how similar disputes are handled in the future, impacting both users and platforms.

The potential US government shutdown poses significant risks, including the delay of the September jobs report and other crucial economic data. This matters because timely employment statistics are vital for understanding the health of the economy and guiding policy decisions. A shutdown could disrupt not only the release of this data but also the overall economic stability, affecting businesses and individuals alike.

Michael Saylor, the executive chairman of MicroStrategy, is making waves with the launch of their new Bitcoin-backed credit product called 'Stretch.' This innovative offering aims to eliminate the volatility and risk typically associated with Bitcoin, making it more accessible for investors. Saylor shared insights on The Close, revealing that MicroStrategy has already introduced four credit instruments this year, totaling an impressive $4 billion, with plans for more in the pipeline. This development is significant as it could reshape how investors engage with cryptocurrency, potentially leading to broader adoption.